Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron Dose Response in Chronic Hepatitis C
NCT00787371Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- Jul 2006
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 2 trial of peginterferon alfa-2b in hepatitis C (HCV), sponsored by Merck & Co.. Started Jun 2005; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00787371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787371.